Pathophysiology of thrombosis and anticoagulation post Fontan surgery

Chantal Attard; Joanna Huang; Paul Monagle; Vera Ignjatovic

doi:10.1016/j.thromres.2018.04.011

Pathophysiology of thrombosis and anticoagulation post Fontan surgery

Chantal Attard
, Joanna Huang
, Paul Monagle
, Vera Ignjatovic

Research output: Contribution to journal › Article › peer-review

Abstract

The Fontan procedure has transformed the lives of children born with single-ventricle physiology, previously deemed inoperable. Worldwide, there are an increasing number of children with Fontan circulation, with the potential for survival into adulthood. Due to the abnormal circulation, Fontan patients have an increased risk of thromboembolic (TE) events, with up to 25% of events leading to death. Despite the importance of preventing TE events in this patient population, there is currently no clinical consensus on the optimal monitoring, thromboprophylaxis therapies, and treatment of these events. This paper reviews the available literature regarding anticoagulation in the pediatric and adult Fontan population, including the mechanisms for thrombosis and current antithrombotic therapies.

Original language	English (US)
Pages (from-to)	204-213
Number of pages	10
Journal	Thrombosis research
Volume	172
DOIs	https://doi.org/10.1016/j.thromres.2018.04.011
State	Published - Dec 2018
Externally published	Yes

Keywords

Anticoagulant therapy
Anticoagulants
Antithrombotic therapy
Fontan

ASJC Scopus subject areas

Hematology

Access to Document

10.1016/j.thromres.2018.04.011

Cite this

@article{36d04eacf02d4c0daa85ddb69d2ae567,

title = "Pathophysiology of thrombosis and anticoagulation post Fontan surgery",

abstract = "The Fontan procedure has transformed the lives of children born with single-ventricle physiology, previously deemed inoperable. Worldwide, there are an increasing number of children with Fontan circulation, with the potential for survival into adulthood. Due to the abnormal circulation, Fontan patients have an increased risk of thromboembolic (TE) events, with up to 25\% of events leading to death. Despite the importance of preventing TE events in this patient population, there is currently no clinical consensus on the optimal monitoring, thromboprophylaxis therapies, and treatment of these events. This paper reviews the available literature regarding anticoagulation in the pediatric and adult Fontan population, including the mechanisms for thrombosis and current antithrombotic therapies.",

keywords = "Anticoagulant therapy, Anticoagulants, Antithrombotic therapy, Fontan",

author = "Chantal Attard and Joanna Huang and Paul Monagle and Vera Ignjatovic",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Ltd",

year = "2018",

month = dec,

doi = "10.1016/j.thromres.2018.04.011",

language = "English (US)",

volume = "172",

pages = "204--213",

journal = "Thrombosis research",

issn = "0049-3848",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Pathophysiology of thrombosis and anticoagulation post Fontan surgery

AU - Attard, Chantal

AU - Huang, Joanna

AU - Monagle, Paul

AU - Ignjatovic, Vera

PY - 2018/12

Y1 - 2018/12

N2 - The Fontan procedure has transformed the lives of children born with single-ventricle physiology, previously deemed inoperable. Worldwide, there are an increasing number of children with Fontan circulation, with the potential for survival into adulthood. Due to the abnormal circulation, Fontan patients have an increased risk of thromboembolic (TE) events, with up to 25% of events leading to death. Despite the importance of preventing TE events in this patient population, there is currently no clinical consensus on the optimal monitoring, thromboprophylaxis therapies, and treatment of these events. This paper reviews the available literature regarding anticoagulation in the pediatric and adult Fontan population, including the mechanisms for thrombosis and current antithrombotic therapies.

AB - The Fontan procedure has transformed the lives of children born with single-ventricle physiology, previously deemed inoperable. Worldwide, there are an increasing number of children with Fontan circulation, with the potential for survival into adulthood. Due to the abnormal circulation, Fontan patients have an increased risk of thromboembolic (TE) events, with up to 25% of events leading to death. Despite the importance of preventing TE events in this patient population, there is currently no clinical consensus on the optimal monitoring, thromboprophylaxis therapies, and treatment of these events. This paper reviews the available literature regarding anticoagulation in the pediatric and adult Fontan population, including the mechanisms for thrombosis and current antithrombotic therapies.

KW - Anticoagulant therapy

KW - Anticoagulants

KW - Antithrombotic therapy

KW - Fontan

UR - https://www.scopus.com/pages/publications/85045697969

UR - https://www.scopus.com/pages/publications/85045697969#tab=citedBy

U2 - 10.1016/j.thromres.2018.04.011

DO - 10.1016/j.thromres.2018.04.011

M3 - Article

C2 - 29685556

AN - SCOPUS:85045697969

SN - 0049-3848

VL - 172

SP - 204

EP - 213

JO - Thrombosis research

JF - Thrombosis research

ER -

Pathophysiology of thrombosis and anticoagulation post Fontan surgery

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this